The 1000th Thread!
This is the 1000th presentation to my bioethics blog since starting on Google Blogspot.com in 2004.There has been many topics covered. Though comments by the visitors has always been encouraged and, since as a " discussion blog " , comments leading to discussions I have felt was the definitive function here. Virtually none of the thread topics have gone unread and most have had some commentary, some with mainly particularly strong and emphatic opinions http://bioethicsdiscussion.blogspot.com/2013/01/should-pathologists-be-physicians.html, some with extensive up to 12 years long continued discussion http://bioethicsdiscussion.blogspot.com/2017/10/patient-modesty-volume-82.html, still there have been some with no visitor response http://bioethicsdiscussion.blogspot.com/2005/01/public-good-vs-money-in-pockets-or.html. It is interesting to understand why such differences have occurred.Though most of the topics were bioethics as related to the subject of medical care, an occasional topic was related to plants http://bioethicsdiscussion.blogspot.com/2014/06/can-tree-experience-hurt-if-it-can-do.html and animals http://bioethicsdiscussion.blogspot.com/2012/04/spending-lot-of-money-on-your-sick-dog.html.Nevertheless, it is the multitude of issues regarding human medical ethics which has dominated this blog. In my opinion, a great listing and summarization of those issues was and is being presented by Wikipedia https://en.wikipedia.org/wiki/List_of_medical_e...
Authors: Reissier S, Cattoir V Abstract INTRODUCTION: Streptogramins (pristinamycin and quinupristin-dalfopristin) can be interesting options for the treatment of infections due to Gram-positive cocci, especially multidrug-resistant isolates. AREAS COVERED: This review provides an updated overview on structural and activity characteristics, mechanisms of action and resistance, pharmacokinetic/pharmacodynamic and clinical use of streptogramins. EXPERT OPINION: The streptogramin antibiotics act by inhibition of the bacterial protein synthesis. They are composed of two chemically distinct compounds, namely typ...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Zhongyi Zhang, Wen-Xiong Wang, Nengjian Zheng, Yansheng Cao, Hongwei Xiao, Renguo Zhu, Hui Guan, Huayun Xiao
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Jinsoo Lee, Seong-Jin Choi, Ji-Seong Jeong, Sang Yun Kim, Sang-Hyub Lee, Mi Jin Yang, Seung-Jin Lee, Young-Jun Shin, Kyuhong Lee, Eun Ju Jeong, Sang-Yoon Nam, Wook-Joon Yu
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Conclusion: These findings suggest that consumption of peanuts high in oleic acid (D7) may have the potential to delay primary fatty liver symptoms. PMID: 33033472 [PubMed]
Publication date: January 2021Source: Safety Science, Volume 133Author(s): Helen Lingard, Tracy Cooke, Greg Zelic, James Harley
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
More News: ADHD | AIDS Vaccine | Anxiety | Argentina Health | AstraZeneca | Australia Health | Babies | Back Pain | Biology | Biomedical Science | Bipolar | Blogging | Boys | Brain | Brain Cancers | Burns | Canada Health | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer Vaccines | Child Abuse | Children | China Health | Clinical Trials | Clonidine | Deep Brain Stimulation | Department of Health | Depression | Dermatology | Disability | Divalproex Sodium | Environmental Health | Eritrea Health | France Health | Gastric (Stomach) Cancer | Gastroenterology | Girls | Government | Guatemala Health | Harvard | Hepatitis | Hepatitis Vaccine | History of Medicine | HIV AIDS | Hospitals | Hungary Health | Huntington's Disease | Impotence | International Medicine & Public Health | Iodine | Lawsuits | Legislation | Lung Transplant | Mania | Medical Ethics | Medical Law | Men | Mitochondrial Disease | Nepal Health | Neurology | Neuroscience | Neurosurgery | Nicotine | Nurses | Nursing | Nutrition | Oatmeal | Oxford University | Pain | Pain Management | Palliative | Palliative Care | Paroxetine | Pathology | Paxil | Perinatology & Neonatology | Politics | Pregnancy | Psychiatry | Psychology | Reproduction Medicine | Risperdal Consta | Romania Health | Schizophrenia | Science | Seroquel | Sexual Abuse | Skin | Skin Biopsy | Sleep Disorders | Sleep Medicine | Speech Therapy | Speech-Language Pathology | Stammer | STDs | Study | Substance Abuse | Suicide | Syphilis | Thyroid | Thyroid Cancer | Toxicology | UK Health | University of Minnesota | USA Health | Vaccines | Veterinary Vaccinations | Wikis | Women | Yale | Zyprexa